Calvin Q. Pan, MD

Dr. Pan is an internationally recognized expert in liver diseases with a research career spanning more than two decades. His work focuses on the natural history of viral hepatitis, antiviral therapy, and disease prevention. He has led more than 50 clinical trials and authored over 170 peer reviewed scientific publications, including first or corresponding author papers in The New England Journal of Medicine, JAMA, Gut, Hepatology, and the Journal of Hepatology.

A pioneer in the prevention of mother to child transmission of hepatitis B, Dr. Pan established one of the earliest risk stratification models for identifying pregnant women at high risk of HBV transmission. His research defined viral load thresholds for perinatal transmission and clarified procedure related risks, including cesarean delivery, vaginal delivery, and amniocentesis. His landmark studies published in NEJM and JAMA demonstrated that maternal tenofovir prophylaxis can reduce maternal viremia at delivery and achieve near zero vertical transmission with a reassuring long term safety profile for infants. These findings have directly shaped global practice and contributed to major updates in both WHO and American Association for the Study of Liver Diseases guidance on hepatitis B management during pregnancy.

Dr. Pan has played leading roles in the development of national and international clinical guidance and consensus statements. He has contributed to 16 practice guidelines and consensus documents addressing hepatitis B management, MASLD, and hepatocellular carcinoma. He has led methodological design and implementation efforts using structured approaches such as the UCLA RAND consensus method for the WGO HBV guidance and liver cancer consensus, applied the GRADE framework for the AASLD 2025 HBV guidelines, and directed a simplified Delphi process for the International Consensus on HBV Related Liver Transplantation.

Dr. Pan has served as Co Chair of the Hepatitis B Practice Guidance and the liver cancer practice guidance for the World Gastroenterology Organization. His prior leadership roles include Chair of the AASLD Hepatitis B Special Interest Group, Co Chair of the AASLD 2025 Hepatitis B Practice Guidelines, Chair of the AASLD Online Learning Committee, Vice President of the Association of Chinese American Physicians, and Board Member of the American Gastroenterological Association’s Political Action Committee.

In recognition of his contributions to science and patient care, Dr. Pan has received the James D. Bruce Memorial Award for Distinguished Contributions in Preventive Medicine from the American College of Physicians, the Outstanding Contribution Award from the Chinese Society of Infectious Diseases, and a Certificate of Service Appreciation from the American Cancer Society. He is a Master of the American College of Physicians and a Fellow of the American Association for the Study of Liver Diseases.